Disclosure of the differences between the consolidated earnings forecast for the second quarter of the fiscal year ending January 2027 and actual results. Operating loss decreased due to revision of manufacturing cost recognition timing and inventory capitalization accompanying drug price listing and launch. Ordinary loss and net loss attributable to owners of the parent also improved due to foreign exchange gains from yen depreciation. For the full-year earnings forecast, no changes are expected.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SunBio Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4592-20260914-03.pdf","jir_short_summary":"Disclosure of the differences between the consolidated earnings forecast for the second quarter of the fiscal year ending January 2027 and actual results. Operating loss decreased due to revision of manufacturing cost recognition timing and inventory capitalization accompanying drug price listing and launch. Ordinary loss and net loss attributable to owners of the parent also improved due to foreign exchange gains from yen depreciation. For the full-year earnings forecast, no changes are expected.","jir_summary":"### Difference between earnings forecast and actual results\nThis release reports the differences between the consolidated earnings forecast and actual results for the second quarter cumulatively for the fiscal year ending January 2027. The operating loss underperformed due to revisions in the timing of manufacturing-related costs recognition and inventory capitalization resulting from drug price listings and launch. Ordinary loss and net loss attributable to owners of the parent improved due to the above operating loss reduction and foreign exchange gains on foreign-currency loans and receivables stemming from yen depreciation. For the full-year earnings forecast, there is no change, as manufacturing-related costs expected to be recognized in the second half are projected to be pushed to the latter half.\n\n### Outlook and cautions\nFactors for the\u5dee\u7570 include the timing of cost recognition and foreign exchange impact, with no change to the full-year forecast. However, attention should be paid to the impact of recognizing manufacturing-related costs in the second half. Future disclosures may be updated if additional differences arise.","jir_financial_highlights":"Operating income: Unknown (Unknown)\nOperating income: \u25b31,909 million yen (Decrease from previous forecast (A) \u25b32,906 million yen)\nOrdinary income: \u25b31,730 million yen (Decrease from previous forecast (A) \u25b32,908 million yen)\nNet income attributable to owners of the parent (interim): \u25b31,791 million yen (Decrease from previous forecast (A) \u25b32,909 million yen)\nper share interim net income: \u25b322.95 yen (Improved from previous forecast (A) \u25b337.28 yen)","jir_category":"","jir_hashtags":"#SunBio, #Earnings, #EarningsDifference, #FXImpact","jir_key_figures":"Operating income: \u25b31,909 million yen\nOrdinary income: \u25b31,730 million yen\nNet income attributable to owners of the parent (interim): \u25b31,791 million yen\nper share interim net income: \u25b322.95 yen\nPrevious forecast (A): Operating income \u25b32,906 million yen\u3001Ordinary income \u25b32,908 million yen\u3001Net income attributable to owners of the parent \u25b32,909 million yen\u3001per share \u25b337.28 yen","jir_meta_title":"SunBio: Disclosure of FY2027 Q2 Earnings Gap | Full-Year Forecast Maintained","jir_meta_description":"SunBio disclosed the differences between the consolidated earnings forecast and actual results for the second quarter cumulatively for the fiscal year ending January 2027. Operating loss improved due to timing revisions of cost recognition and inventory capitalization, and FX gains contributed to improvement. No change to the full-year forecast.","jir_og_title":"SunBio | Disclosure of FY2027 Q2 Earnings Gap","jir_og_description":"SunBio disclosed the differences between the earnings forecast and actual results for the second quarter cumulatively. Improvement in net loss due to timing revisions of cost recognition and FX gains; full-year forecast maintained. See IR materials for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-113806","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n